


## CLAIMS

We claim:

1. A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof:

wherein:

A is C<sub>1</sub>-C<sub>4</sub> alkenylene or C<sub>1</sub>-C<sub>4</sub> alkynylene;

R is C<sub>1</sub>-C<sub>4</sub> alkylene;

R¹ is the group defined by -(Z)-(Z¹)<sub>m</sub>-(Z²)<sub>n</sub>, wherein

Z is aryl, heteroaryl, heteroarylene, or arylene,

Z¹ is C(H)<sub>2</sub>, where m is 0 or 1,

Z² is OR', -SR', -N(R')R'', halo, C<sub>1</sub>-C<sub>3</sub> alkyl, -CN, -C(O)R', -C(O)N(R')R'', or heterocyclyl, where n is 0 or 1;

R' is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;

R'' is -H, -C(O)R''', -C(S)R''', -ROR''', -C(=NH)N(R')R'', C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl, cyanoalkyl, -S(O)<sub>2</sub>R''', -RS(O)<sub>2</sub>R''', -C(O)N(R')R''', -C(O)N(R')R<sup>a</sup>, -C(O)RS(O)<sub>2</sub>R''', -C(O)ROROR''', -C(O)RSR''', -C(O)RNR'R'', -C(O)RC(O)OR''', -RN(R')RN(R')C(O)R''', heterocyclyl, or aralkyl;

R''' is C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> haloalkyl, C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl, cyanoalkyl, or aryl;

R<sup>a</sup> is -RS(O)<sub>2</sub>R', aralkyl, or -ROR''';

R² is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;


$R^3$  is the group defined by  $-(Q)-(Q^1)_r-(Q^2)$ , wherein

Q is arylene or heteroarylene

$Q^1$  is O, where r is 0 or 1, and

$Q^2$  is aralkyl, heteroaryl, or aryl.

2. A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof:  
wherein:

A is  $C \equiv C$ ;

R is  $C_1$ - $C_4$  alkylene;

$R^1$  is the group defined by  $-(Z)-(Z^1)_m-(Z^2)_n$ , wherein

Z is aryl, heteroaryl, heteroarylene, or arylene,

$Z^1$  is  $C(H)_2$ , where m is 0 or 1,

$Z^2$  is  $OR'$ ,  $-SR'$ ,  $-N(R')R''$ , halo,  $C_1$ - $C_3$  alkyl,  $-CN$ ,  $-C(O)R'$ ,  $-C(O)N(R')R''$ , or heterocyclyl, where n is 0 or 1;

$R'$  is  $-H$  or  $C_1$ - $C_3$  alkyl;

$R''$  is  $-H$ ,  $-C(O)R'''$ ,  $-C(S)R'''$ ,  $-ROR'''$ ,  $-C(=NH)N(R')R''$ ,  $C_1$ - $C_3$  alkyl,  $C_1$ - $C_3$  hydroxyalkyl, cyanoalkyl,  $-S(O)_2R'''$ ,  $-RS(O)_2R'''$ ,  $-C(O)N(R')R'''$ ,  $-C(O)N(R')R^a$ ,  $-C(O)RS(O)_2R'''$ ,  $-C(O)ROR'''$ ,  $-C(O)RSR'''$ ,  $-C(O)RNR'R''$ ,  $-C(O)RC(O)OR'''$ ,  $-RN(R')RN(R')C(O)R'''$ , heterocyclyl, or aralkyl;

$R'''$  is  $C_1$ - $C_3$  alkyl,  $C_1$ - $C_3$  haloalkyl,  $C_1$ - $C_3$  hydroxyalkyl, cyanoalkyl, or aryl;

$R^a$  is  $-RS(O)_2R'$ , aralkyl, or  $-ROR'''$ ;

$R^2$  is  $-H$  or  $C_1$ - $C_3$  alkyl;


$R^3$  is the group defined by  $-(Q)-(Q^1)_r-(Q^2)$ , wherein

Q is arylene or heteroarylene

$Q^1$  is O, where r is 0 or 1, and


$Q^2$  is aralkyl, heteroaryl, or aryl.

3. A compound as claimed in claim 1, wherein A is  $C_1$ - $C_4$  alkynylene.
4. A compound as claimed in claim, wherein A is  $C \equiv C$ .
5. A compound as claimed in claim 1, wherein A is  $C_1$ - $C_4$  alkenylene.
6. A compound as claimed in claim 1, wherein A is  $C=C$ .
7. A compound as claimed in claim 1, wherein Z is heteroaryl and m and n are each 0.
8. A compound as claimed in claim 1, wherein Z is selected from




9. A compound as claimed in claim 1, wherein Z is heteroarylene, m is 0 or 1 and n is 1.
10. A compound as claimed in claim 1, wherein Z is selected from

121



11. A compound as claimed in claim 1, wherein Z is aryl, and m and n are each 0.


12. A compound as claimed in claim 1, wherein Z is



m and n are 0.

13. A compound as claimed in claim 1, wherein Z is arylene, m is 0 or 1 and n is 1.

14. A compound as claimed in claim 1, wherein Z is




15. A compound as claimed in claim 1, wherein R<sup>2</sup> is -H.


16. A compound as claimed in claim 1, wherein R<sup>2</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl.

17. A compound as claimed in claim 1, wherein Q is arylene, Q<sup>1</sup> is O and r is 1, and Q<sup>2</sup> is aralkyl, aryl, or heteroaryl.

18. A compound as claimed in claim 1, wherein Q is




where R<sup>4</sup> is -H or halo, Q<sup>1</sup> is O, r is 1, and Q<sup>2</sup> is selected from




where R<sup>5</sup> is halo.

19. A compound as claimed in claim 1, wherein Q is arylene, r is 0, and Q<sup>2</sup> is aralkyl.

20. A compound as claimed in claim 1, wherein Q is selected from



r is 0, and Q<sup>2</sup> is selected from



21. A compound as claimed in claim 1 selected from the group:

2-benzyl-*N*-{5-[(*E*)-2-phenylethenyl]pyrimidin-4-yl}-1*H*-benzimidazol-5-amine;

2-benzyl-*N*-{5-[(*E*)-2-thien-3-ylethenyl]pyrimidin-4-yl}-1*H*-benzimidazol-5-amine;

2-benzyl-*N*-{5-[(*E*)-2-(1*H*-pyrazol-4-yl)ethenyl]pyrimidin-4-yl}-1*H*-benzimidazol-5-amine;

3-[(*E*)-2-{4-[(2-benzyl-1*H*-benzimidazol-5-yl)amino]pyrimidin-5-yl}ethenyl]-*N*-methylbenzamide;

2-benzyl-*N*-{5-[(*E*)-2-thien-3-ylethenyl]pyrimidin-4-yl}-1,3-benzothiazol-5-amine;

1-benzyl-*N*-{5-[(*E*)-2-pyridin-3-ylethenyl]pyrimidin-4-yl}-1*H*-indazol-5-amine;

1-benzyl-*N*-{5-[(*E*)-2-pyridin-4-ylethenyl]pyrimidin-4-yl}-1*H*-indazol-5-amine;

2-[(*E*)-2-{4-[(1-benzyl-1*H*-indazol-5-yl)amino]pyrimidin-5-yl}ethenyl]pyridin-3-ol;

1-benzyl-*N*-{5-[(*E*)-2-(1*H*-pyrazol-4-yl)ethenyl]pyrimidin-4-yl}-1*H*-indazol-5-amine;

*N*-{5-[(*E*)-2-(2-aminopyrimidin-5-yl)ethenyl]pyrimidin-4-yl}-1-benzyl-1*H*-indazol-5-amine;

*N*-[3-[(*E*)-2-{4-[(1-benzyl-1*H*-indazol-5-yl)amino]pyrimidin-5-yl}ethenyl]phenyl]acetamide;

*N*-(4-phenoxyphenyl)-5-[(*E*)-2-phenylethenyl]pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-pyridin-3-ylethenyl]pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-pyridin-4-ylethenyl]pyrimidin-4-amine;

2-[(*E*)-2-{4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl}ethenyl]pyridin-3-ol;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-thien-2-ylethenyl]pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-thien-3-ylethenyl]pyrimidin-4-amine;

5-[(*E*)-2-[4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethenyl]pyrimidin-2-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-(1*H*-pyrazol-4-yl)ethenyl]pyrimidin-4-amine;

*N*-(3-[(*E*)-2-[4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethenyl]phenyl)acetamide;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-(3,4-dimethoxyphenyl)ethenyl]pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(*E*)-2-phenylethenyl]pyrimidin-4-amine;

*N*-(5-[(*E*)-2-[4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethenyl]pyridin-2-yl)acetamide;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(thien-2-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(pyridin-3-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1-methyl-1*H*-imidazol-5-yl)ethynyl]pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(1*H*-pyrazol-4-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(pyrimidin-5-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(1,3-thiazol-2-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(thien-3-ylethynyl)pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(2-morpholin-4-yl)pyrimidin-4-yl]ethynyl]pyrimidin-4-amine;

*N*-(3-chloro-4-[(3-fluorophenyl)methyl]oxy}phenyl)-5-(2-pyrimidinylethynyl)-4-pyrimidinamine;

5-[(6-amino-3-pyridinyl)ethynyl]-*N*-(3-chloro-4-[(3-fluorophenyl) methyl]oxy} phenyl)-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(3-fluorophenyl) ethynyl]pyrimidin-4-amine;

4-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenol;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(6-methoxypyridin-2-yl)ethynyl]pyrimidin-4-amine;

5-[(3-aminophenyl)ethynyl]-*N*-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}pyrimidin-4-amine;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)acetamide;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)ethanethioamide;

2-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzonitrile;

3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzonitrile;

3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzaldehyde;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(phenylethynyl) pyrimidin-4-amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-(pyridin-2-ylethynyl)pyrimidin-4-amine;

5-[(4-aminophenyl)ethynyl]-*N*-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}pyrimidin-4-amine;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)-3-(methylthio)propanamide;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-({1-[(4-methylphenyl) sulfonyl]-1*H*-indol-6-yl}ethynyl)pyrimidin-4-amine;



*tert*-butyl-3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzylcarbamate; pyrimidin-5-

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)guanidine;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzyl)acetamide;

*N*-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-5-[[3-({[2-(methylsulfonyl)ethyl]amino}methyl)phenyl]ethynyl]pyrimidin-4-amine;

5-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]-2-furaldehyde;

3-[[[5-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]-2-furyl)methyl]amino]propanenitrile;

(5-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]-2-furyl)methanol;

(4-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]-1,3-thiazol-2-yl)methanol;

*N*-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-5-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)pyrimidin-4-amine;

2-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]benzaldehyde;

*N*-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-5-[[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]ethynyl]pyrimidin-4-amine;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)-2-(2-methoxyethoxy)acetamide;

*N*-[3-({4-[(2-benzyl-1*H*-benzimidazol-5-yl)amino]pyrimidin-5-yl}ethynyl)phenyl]acetamide;

*N*'-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)- $\beta$ -alaninamide;

*N*-(3-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]phenyl)-2-(methylsulfonyl)acetamide;

*N*-[3-({4-[(4-benzylphenyl)amino]pyrimidin-5-yl}ethynyl)phenyl]-acetamide;

*N*-[3-({4-[(4-phenoxyphenyl)amino]pyrimidin-5-yl}ethynyl)phenyl] acetamide;

*N*-[3-({4-[(1-benzyl-1*H*-indazol-5-yl)amino]pyrimidin-5-yl}ethynyl) phenyl]acetamide;

1-benzyl-*N*-[5-(phenylethynyl)pyrimidin-4-yl]-1*H*-indol-5-amine;

5-[(6-amino-2-pyridinyl)ethynyl]-*N*-(3-chloro-4-[(3-fluorophenyl) methyl]oxy}phenyl)-4-pyrimidinamine;

*N*-{6-[2-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl) ethynyl]-2-pyridinyl} acetamide;

2-chloro-*N*-{6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}-2,2-difluoroacetamide;

*N*-{6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl) ethynyl]-2-pyridinyl}-4-(dimethylamino)butanamide;

methyl 4-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}amino)-4-oxobutanoate;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(6-{[2-(methylsulfonyl)ethyl]amino}-2-pyridinyl)ethynyl]-4-pyrimidinamine;

{6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methanol;

2-[(6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl)methyl](methyl)amino]ethanol;

3-[(6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl) ethynyl]-2-pyridinyl)methyl]amino]propanenitrile;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(6-({2-(4-morpholinyl)ethyl]amino)methyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine;

*N*-{2-[(6-[2-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl)methyl]amino]ethyl}acetamide;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(6-({3-(1*H*-imidazol-1-yl)propyl]amino)methyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-({6-[(methylamino) methyl]-2-pyridinyl} ethynyl)-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-{[6-(methoxymethyl)-2-pyridinyl]ethynyl}-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-{[2-(methylsulfanyl)-4-pyrimidinyl]ethynyl}-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-({6-[(dimethylamino) methyl]-2-pyridinyl} ethynyl)-4-pyrimidinamine;

*N*-benzyl-*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)amine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-({6-[[2-methoxyethyl]amino]methyl}-2-pyridinyl)ethynyl]-4-pyrimidinamine;

5-{[6-(aminomethyl)-2-pyridinyl]ethynyl}-*N*-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-4-pyrimidinamine;

*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl) ethynyl]-2-pyridinyl} methyl)-*N'*-(2-cyanoethyl)urea;

*N'*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)-*N*-(2-hydroxyethyl)-*N*-methylurea;

*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)-*N'*-[2-(methylsulfonyl)ethyl]urea;

*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)-*N'*-[2-(4-morpholinyl)ethyl]urea;

*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)-*N'*-methylurea;

*N*-({6-[(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-5-pyrimidinyl)ethynyl]-2-pyridinyl}methyl)-*N'*-(2-methoxyethyl)urea;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-{[6-(1-piperidinylmethyl)-2-pyridinyl]ethynyl}-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-({6-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl}ethynyl)-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[[6-(4-morpholinyl-methyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[[6-(1-pyrrolidinyl-methyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine;

*N*-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[[6-(1-piperazinylmethyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine;

4-amino-2-[[4-({3-chloro-4-[(4-fluorobenzyl)oxy]phenyl}amino) pyrimidin-5-yl] ethynyl] pyrimidine-5-carbonitrile;

2-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]-4-[[2-(methylsulfonyl)ethyl]amino]pyrimidine-5-carbonitrile;

4-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]pyrimidin-2-amine; and

*N*-(6-[[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]ethynyl]pyridin-2-yl)-2,2,2-trifluoroacetamide;

or a salt, solvate, or physiologically functional derivative thereof.

22. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 21, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

23. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate activity of at least one erbB family kinase, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 21, or a salt, solvate or a physiologically functional derivative thereof.

24. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate activity of at least two erbB family kinases, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 21, or a salt, solvate or a physiologically functional derivative thereof.

25. A compound as claimed in any one of claims 1 to 21, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

26. Use of a compound as claimed in any one of claims 1 to 21, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate activity of at least one erbB family kinase.

27. Use of a compound as claimed in any one of claims 1 to 21, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate activity of at least two erbB family kinases.